New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye

Phase 4

Not yet recruiting

• Conditions: Dry Eye Disease (DED)

• Registration Number: NCT06903741
• Lead Sponsor: Laboratoires Thea

Brief Summary

The goal of this prospective, non-randomized, non-comparative, monocentric PMCF study is to assess the performance of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA on DED at 6 months in 30 patients having dry eye disease.

The main questions it aims to answer are:

* To assess the performance and safety of T2769 at 3 months and 6 months.

* To assess patient compliance to therapy.

* To assess the occurrence of dry eye flares. Participants will be asked to use T2769 on a daily basis and complete a self-questionnaire throughout the study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-03-21
• Study First Submitted QC: 2025-03-28
• Status Verified: 2025-04
• Study First Posted: 2025-04-01
• Last Update Submitted: 2025-04-23
• Last Update Posted: 2025-04-25
• Study Start: 2025-07
• Primary Completion: 2025-10
• Study Completion: 2026-03

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Men and women aged over 18 years,
• Able to give written informed consent prior the initiation of any procedure,
• History of dry eye syndrome for at least 3 months,
• OSDI ≥13,
• Never been treated with artificial tears or with no artificial tears at least 1 month before the enrolment, or not satisfied with current artificial tears.

Exclusion Criteria

Systemic/non Ophthalmic Exclusion Criteria

• Known or suspected hypersensitivity to one of the components of the IMD,
• History of or active relevant systemic condition incompatible with the investigation or likely to interfere with the investigation results or the patient safety according to investigator judgment.

Specific Exclusion Criteria Regarding Childbearing Potential Women

• Pregnant or breast-feeding women,
• Childbearing potential women neither surgically sterilised nor using an adequate contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring, patch) .

Exclusion Criteria Related to General Conditions

• Alcohol addiction and heavy smoker according to investigator's judgement,
• Unable to understand the investigation procedures or to give informed consent,
• Non-compliant (e.g., not willing to attend a visit or completing the self-questionnaire; way of life interfering with compliance),
• Participant in this investigation at the same time as another clinical investigation/study,
• Participant in this investigation within the exclusion period of a previous study/investigation with a minimum of one month,
• Participant being institutionalized because of legal or regulatory order, inmate of psychiatric wards, prison or state institutions, or employee or family member of the investigation sites or of the Sponsor's company.

Exclusion criteria related to previous and concomitant treatments (medications/non-medicinal therapies/procedures)

• Participant with previous, current or anticipated prohibited listed treatment (or prohibited modification of treatment regimen).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Improvement of DED signs and symptoms at 6 months (M6) according to Ocular Surface Disease Index (OSDI) score change from baseline to M6	at baseline, at 3 months, at 6 months	Improvement of DED signs and symptoms at 6 months (M6) according to Ocular Surface Disease Index (OSDI) score change from baseline to M6 OSDI is a 12-item scale with total score from 0 to 100 (Mild 13-22; moderate 23-32; severe 33-100)